Horm Metab Res 1985; 17(1): 1-4
DOI: 10.1055/s-2007-1013432
ORIGINALS
Basic
© Georg Thieme Verlag, Stuttgart · New York

Enhancement of Insulin Release and Islet Cell Calcium Content by an Acyl-Amino-Alcyl Benzoic Acid Derivative, HB 699

R. Puech1 , M. Manteghetti1 , G. Ribes1 , C. B. Wollheim2 , M. M. Loubatières-Mariani1
  • 1Laboratoire de Pharmacologie et de Pharmacodynamie, Equipe de Recherche Associée au CNRS no 786, Institut de Biologie, Faculté de Médecine, Montpellier, France
  • 2Institut de Biochimie Clinique, University of Geneva, Geneva, Switzerland
Further Information

Publication History

1983

1983

Publication Date:
14 March 2008 (online)

Summary

HB 699, a hypoglycaemic agent which lacks the structural requirements regarded as essential for the insulin releasing action of the sulfonamide group, was studied in isolated rat islets and compared with tolbutamide. In the presence of 8.3 mM glucose for long exposure (24 h) both substances induced an increase of insulin release without altering the islet insulin content. After preloading of the islets to isotopic equilibrium with 45Ca++ (24 h), HB 699 and tolbutamide induced a significant increase in total exchangeable calcium content parallelled by an increase in insulin release. Both effects could be suppressed by verapamil, a blocker of voltage-sensitive Ca++ channels. These results indicate that HB 699, like tolbutamide, stimulates insulin release by increasing Ca++ uptake by the B cells.